Company profile: Acesion Pharma
1.1 - Company Overview
Company description
- Provider of medical drugs for the treatment of atrial fibrillation, developing therapies that inhibit a heart cell ion channel. Offerings include AP30663, an intravenous drug for acute cardioversion to sinus rhythm with demonstrated efficacy in clinical trials, and AP31969, an oral drug for maintenance of sinus rhythm in patients with atrial fibrillation, currently in clinical development.
Products and services
- Ion-Channel Inhibition AF Drug Development: The company architects medical drugs that treat atrial fibrillation by inhibiting heart-cell ion channels involved in generating electrical activity, underpinning acute and maintenance therapies
- Mechanism-driven
- AP31969: An oral drug created to maintain sinus rhythm in atrial fibrillation patients, currently advancing through clinical development for chronic rhythm stabilization
- Oral-formulation
- AP30663: An intravenous drug engineered for acute cardioversion of atrial fibrillation to sinus rhythm, demonstrating efficacy in clinical trials for rapid restoration in acute care
- Intravenous-formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Acesion Pharma
R3 Vascular
HQ: United States
Website
- Description: Provider of medical devices for peripheral artery disease, including the MAGNITUDE Bioresorbable Sirolimus-Eluting Scaffold (BRS), which maintains vessel support, delivers sirolimus to prevent restenosis, and gradually resorbs into tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full R3 Vascular company profile →
Action Pharma
HQ: Denmark
Website
- Description: Provider of R&D-focused drug discovery and development, creating pharmaceutical products and treatment concepts for cardiovascular and inflammatory diseases and acquired metabolic diseases, including type-II diabetes and obesity; product pipeline includes AP214.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Action Pharma company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
Millipede Medical
HQ: United States
Website
- Description: Provider of a percutaneous, catheter-based solution for mitral valve repair and treatment of mitral and tricuspid regurgitation, restoring health and expanding options for physicians and patients globally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Millipede Medical company profile →
Exithera Pharmaceuticals
HQ: United States
Website
- Description: Provider of antithrombotic and stroke prevention drug development, offering novel, potent, selective small-molecule Factor XIa inhibitors, including frunexian to prevent thrombosis without increased bleeding risk, and EP-7041 evaluated in a Phase 2 trial to prevent thrombosis in COVID-19 ICU patients and investigated to inhibit ECMO-related thrombosis while minimizing bleeding risk.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exithera Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Acesion Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Acesion Pharma
2.2 - Growth funds investing in similar companies to Acesion Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Acesion Pharma
4.2 - Public trading comparable groups for Acesion Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →